Receive The Newest Study Notifications

HOUSTON, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announces the...

In a paper published in today's online issue of the Journal of Alzheimer's Disease (DOI 10.3233/JAD-190772), TauRx has reported unexpected results of a pharmacokinetic analysis of the relationship between treatment dose, blood levels and pharmacological activity of...

IMVT-1401, a fully human anti-FcRn antibody designed to be administered via subcutaneous injection, is the only anti-FcRn antibody known to be in clinical development for the treatment of GO Topline results from the ASCEND-GO 2 program are expected in early 2021...

GENFIT: Positive 42-month DSMB Recommendation for Continuation of Phase 3 RESOLVE-IT Study of Elafibranor in NASH Data Safety Monitoring Board (DSMB) recommends the continuation of the RESOLVE-IT clinical trial without any modifications, based on the pre-planned...

With the advent of digital media, the ability to reach a wide audience has never been easier. A patient recruitment company isn't limited to traditional methods, as digital platforms can be a vital tool when implemented to reach patients for future trials. Despite the...

Vaccitech progresses clinical development of Universal Influenza A Vaccine (VTP-100) in Belgium and Australia and expects top-line data in early 2020 Vaccitech Ltd, a clinical-stage T cell immunotherapy company developing products to treat and prevent cancer and...

--RRx-001 led to an overall survival of 21.9 months and progression-free survival of 13 months-- --Data presented at the Society for Neuro-Oncology annual meeting-- LA JOLLA, CA, USA I November 25, 2019 I EpicentRx, Inc., a clinical cancer immunotherapy company...

This is the world's first IRB-approved clinical trial aimed at reversing aging by at least 20 years; it is also the world's most expensive pay-to-play trial with a one million price tag to enroll. MANHATTAN, Kan., Nov. 21, 2019 /PRNewswire/ -- Libella Gene...

For years Canndoc has been successfully supplying medical cannabis-based products that providing efficient treatment for children diagnosed with autism spectrum disorder Canndoc's medicinal cannabis clinical pipeline includes 9 approved Phase 2 clinical trials...

ClearFlow, Inc., a medical device company based in Irvine, California, has announced positive clinical trial results published in the peer-reviewed Journal of Cardiothoracic Surgery. The trial evaluated the use of the PleuraFlow® Active Clearance Technology® (ACT®)...

BEIJING, Nov. 22, 2019 /PRNewswire/ -- China Ophthalmology Focus Limited ("COPFL") today announced that its wholly-owned subsidiary, Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Limited ("ZKO") has successfully completed patient enrollment of the Phase III study of...

Key Points Immuron completes first meeting with FDA on development of IMM-124E as product to specifically prevent Travelers’ Diarrhea (TD) Phase 3 clinical trial of IMM-124E to prevent TD planned for 2020 Previous clinical trial data on IMM-124E from earlier studies...

Enrollment Rate Exceeds Expectation, Suggesting High Unmet Need and Anticipation for Bermekimab in HS AUSTIN, Texas, Nov. 19, 2019 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) today announces rapid enrollment in its randomized, double-blind, placebo-controlled...

- MOMENTUM trial designed to confirm the unique benefits of momelotinib on all three hallmarks of myelofibrosis: symptoms, anemia and enlarged spleen -- Targeting enrollment of 180 symptomatic and anemic patients previously treated with a JAK inhibitor –- Top-line...

With the French Regulatory Approval by ANSM, the clinical trial is fully approved in 15 countries The clinical trial with once a day oral dosing is being conducted in 232 patients with moderate to severe ulcerative colitis in about 150 study sites As announced during...

The STEADFAST clinical study of TX200 is the first-in-human trial to evaluate a CAR-Treg cell therapy BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the United Kingdom’s (UK) Medicines...

Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Range of VK2809 Doses for up to 52 Weeks SAN DIEGO, Nov. 19, 2019 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the...

Westport, CT, Nov. 21, 2019 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (BSGM) (“BioSig” or the “Company”), a medical technology company developing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of...

COPE-WEL study aims to validate Headstart® test for early detection and monitoring of pulmonary exacerbation of COPD • Headstart is a non-invasive self-test that detects lung biomarkers in the urine • Observational, multi-centre validation trial carried out in...

HOPKINTON, Mass., Nov. 20, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today...